SEC Form 4 · accession 0001209191-17-063918
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matt Abernethy
Officer — Chief Financial Officer
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $73.60 | Dec 1, 2017 | A | 60,000 | A | — | Dec 1, 2027 | Common Stock | 60,000 | 60,000 | D |
| Restricted Stock UnitF2,F3 | — | Dec 1, 2017 | A | 12,500 | A | — | — | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on December 1, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
- F2Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F3The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021.